1 Introduction Glioblastoma (GBM, WHO grade IV) is the most aggressive form of primary brain tumor, with a median survival of 14–17 months in affected patients [1-3]. Temozolomide (TMZ) secured approval for GBM treatment on the basis of evidence derived from a randomized phase III clinical trial [4]. Despite the rapid emergence of TMZ resistance in the majority of GBM patients, this agent remains the first-line chemotherapeutic of choice for the disease [5].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Guangsong
Contact Guangsong, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack